In vivo CAR-T: Is there a growing shortage of target antigens?
Chinese enterprises are emerging as an undeniable force.
Time：
2026-04-29 08:23
Author：
xieyijun
A Biotech Veteran's Entrepreneurship Playbook: Turning Missteps into Stepping Stones
In-Depth Dialogue with Wei Cao: Decoding Biotech Entrepreneurship
Time：
2026-04-26 17:33
Author：
xieyijun
Where lies the next BD opportunity amid the fiercely competitive PD‑1/VEGF landscape?
Time：
2026-04-25 14:42
Author：
xieyijun
Under a dual-mode narrative, Na'an Biotech launches a coordinated offensive.
A technical system equipped with collaborative interfaces is now fully ready.
Time：
2026-04-24 08:19
Author：
xieyijun
This In Vivo CAR-T Company: Why Has It Caught the Eye of Three Major MNCs?
Time：
2026-04-21 08:38
Author：
xieyijun
Biomedical New Technologies Face a Sea Change: Life and Death Under New Regulations
Time：
2026-04-19 17:44
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务